FLT3 and acute myeloid leukemia: The MORPHO clinical trial was a phase III trial conducted by the blood and marrow transplant clinical trials network (BMT-CTN) evaluating gilteritinib as a maintenance therapy following allogeneic HSCT for patients with FLT3-ITD mutated AML.